Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NIH approps

This article was originally published in The Tan Sheet

Executive Summary

NCCAM would receive $116.2 mil. in FY 2004 funding under House Labor/HHS appropriations bill, which passed by 215-208 vote July 10. Level matches Bush Administration proposal and represents budget increase of about 3.6%, which would be smallest funding growth since center's inception (1"The Tan Sheet" Feb. 10, 2003, p. 7). NIH would be advanced $28 bil. in FY 2004, an increase of $681 mil. that matches Bush Administration's budget request...

You may also be interested in...

Washington In Brief

Burton gets subcommittee chair: Former House Government Reform Committee Chair Dan Burton (R-Ind.) named to oversee newly created Subcommittee on Wellness & Human Rights, Committee Chair Tom Davis (R-Va.) announces Jan. 31. Subcommittee will address issues concerning public health policy, human rights and family health, according to Davis' office. Votes to confirm the subcommittee and chairman appointment will be taken when the full Government Reform Committee convenes, possibly the week of Feb. 10. In his new position, Burton likely will revisit dietary supplement-related issues, which were the subject of frequent hearings during his tenure as full committee chair...

Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning

Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.

Coronavirus Update: The Hunt For A Vaccine & Non-COVID-19 Trial Plans Go Awry

In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts